ProMIS Neurosciences, Inc. (PMN.TO)
| Previous Close | 0.1850 |
| Open | 0.1850 |
| Bid | 0.1750 x 0 |
| Ask | 0.1800 x 0 |
| Day's Range | 0.1750 - 0.1900 |
| 52 Week Range | 0.0800 - 0.2800 |
| Volume | 758,617 |
| Avg. Volume | 332,950 |
| Market Cap | 61.416M |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | Mar. 31, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
ProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021
TORONTO and CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the Second Annual Undruggable Leaders Forum, a virtual event to be held on September 15-16. ProMIS Chief Development Officer, Dr. Johanne Kaplan, will be presenting he
- GlobeNewswire
ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 23rd Annual Investment Conference
TORONTO and CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in H.C. Wainwright & Co., 23rd Annual Investment Conference being held virtually September 13-15 2021. ProMIS Executive Chairman, Eugene Williams, will provide an update
- GlobeNewswire
ProMIS Neurosciences appoints accomplished biotechnology executive, Josh Mandel-Brehm, to its Board of Directors
TORONTO and CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Josh Mandel-Brehm to its Board of Directors with immediate effect. “I am delighted to welcome Josh Mandel-Brehm as a member of the ProMIS Board of Directors
